Takeda strikes $500M+ deal for California biotech's ALS program
Takeda is betting more than half a billion dollars on a California biotech’s approach to treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The Japanese pharma giant has inked a $580 million deal (including an undisclosed upfront payment and potential milestones) for AcuraStem’s PIKFYVE therapies, including an ALS candidate nearing the clinic called AS-202. By suppressing levels of the PIKFYVE kinase, which was recently identified as a target for ALS, AcuraStem hopes it can clear out toxic protein aggregates and protect neuronal function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.